http://fdanews.com/newsletter/article?issueId=10753&articleId=98762
quote:
The firm said it recently has invested more than $2 billion to expand its manufacturing capacity for the vaccines, as well as for capacity of its inhaled antiviral flu treatment Relenza (zanamivir).
end quote: